Pathogenesis of hepatic encephalopathy: Role of ammonia and systemic inflammation

Journal of Clinical and Experimental Hepatology

Volumn 5, Issue S1, 2015, Pages S7-S20

  Aldridge, Dominic R ^a   Tranah, Edward J ^a   Shawcross, Debbie L ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Ammonia; Hepatic encephalopathy; Infection; Inflammation; Systemic inflammatory response syndrome

Indexed keywords

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; AMMONIA; CYCLOOXYGENASE 2; GAMMA INTERFERON; GELATINASE B; GLUTAMATE AMMONIA LIGASE; GLUTAMINE; HUMAN ALBUMIN; IBUPROFEN; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MINOCYCLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PROBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; RIFAXIMIN; RIFAXIMIN ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE LIVER FAILURE; ALBUMIN DIALYSIS; AMMONIA BLOOD LEVEL; AMMONIA METABOLISM; ASTROCYTE; BLOOD BRAIN BARRIER; CHRONIC LIVER FAILURE; CITRIC ACID CYCLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TARGETING; HEPATIC ENCEPHALOPATHY; HUMAN; IMMUNOPATHOLOGY; INDUCED HYPOTHERMIA; INFLAMMATION; INNATE IMMUNITY; METABOLIC REGULATION; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; MOLECULAR DYNAMICS; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NITROGEN METABOLISM; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SYMPTOM; SYSTEMIC INFLAMMATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84924624777     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2014.06.004     Document Type: Review

References (126)

1. Trey C., Davidson C.S. The management of fulminant hepatic failure. Prog Liver Dis 1970, 3:282-298.
2. Bernal W., Hall C., Karvellas C., Auzinger G., Sizer E., Wendon J. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 2007, 46(6):1844-1852.
3. Blei A.T. Medical therapy of brain edema in fulminant hepatic failure. Hepatology 2000 September, 32(3):666-669.
4. Bernal W., Hyyrylainen A., Gera A., et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. JHepatol 2013 July, 59(1):74-80.
5. Joshi D., O'Grady J., Patel A., et al. Cerebral oedema is rare in acute-on-chronic liver failure patients presenting with high-grade hepatic encephalopathy. Liver Int 2013 June 20, [Epub ahead of print]. 10.1111/liv.12257.
6. Shawcross D.L., Austin M.J., Abeles R.D., et al. The impact of organ dysfunction in cirrhosis: survival at a cost?. JHepatol 2011 Apr, 54(4):640-649.
7. Weissenborn K., Ennen J., Schomerus H., Ruckert N., Hecker H. Neuropsychological characterization of hepatic encephalopathy. JHepatol 2001, 34:768-773.
8. Bajaj J.S., Cordoba J., Mullen K.D., et al. Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011 April, 33(7):739-747.
9. Das A., Dhiman R.K., Saraswat V.A., Verma M., Naik S.R. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. JGastroenterol Hepatol 2001 May, 16(5):531-535.
10. Hahn M., Massen O., Nencki M., Pavlov I. Die Eck'sche fistel zwischen der unteren hohlvene und der pfortader und ihre folgen fur den organismus. Arch Exp Pathol Pharm 1893, 32:161-210.
11. Nencki M., Zaleski J. Ueber die Bestimmung des Ammoniaks in Thierischen Fluessigkeiten und Geweben. Arch Fuer Exp Pathol Pharmakol 1895, 36:385-396.
12. Nencki M., Pawlow J., Zaleski J. Ueber den ammoniakgehalt des blutes under der organe und die harnstoffbildung bei den saugethieren. Arch Fuer Exp Pathol Pharmakol 1896, 37:26-51.
13. Shawcross D.L., Olde Damink S.W.M., Butterworth R.F., Jalan R. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab Brain Dis 2005, 20(3):169-179.
14. Gabuzda G.J., Phillips G., Davidson C. Reversible toxic manifestations in patients with cirrhosis of the liver given cation-exchange resins. NEJM 1952, 246:124-130.
15. Phillips G., Schwartz R., Gabuzda G., Davidson C. The syndrome of impending hepatic coma in patients with cirrhosis of the liver given certain nitrogenous substances. NEngl J Med 1952, 247:239-246.
16. Traeger H., Gabuzda S., Ballou A., Davidson C. Blood ammonia concentration in liver disease and liver coma. Metabolism 1954, 3:99-109.
17. Stahl J. Studies of the blood ammonia in liver disease: its diagnostic, prognostic and therapeutic significance. Ann Intern Med 1963, 58:1-24.
18. Phear E., Sherlock S., Summerskill W. Blood ammonium levels in liver disease and hepatic coma. Lancet 1955, 7:836-840.
19. Shawcross D.L., Sharifi Y., Canavan J.B., et al. Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. JHepatol 2011 April, 54(4):640-649.
20. Ong J.P., Aggarwal A., Krieger D., et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003 February 15, 114(3):188-193.
21. Clemmesen J., Larsen F., Kondrup J., Hansen B., Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999, 29:648-653.
22. Kumar R., Shalimar, Sharma H., et al. Persistent hyperammonemia is associated with complications and poor outcomes in patients with acute liver failure. Clin Gastroenterol Hepatol 2012 August, 10(8):925-931.
23. Liaw S.H., Kuo I., Eisenberg D. Discovery of the ammonium substrate site on glutamine synthetase, a third cation binding site. Protein Sci 1995 November, 4(11):2358-2365.
24. Cooper A.J., Lai J.C. Cerebral ammonia metabolism in normal and hyperammonemic rats. Neurochem Pathol 1987 February, 6(1-2):67-95.
25. Martinez-Hernandez A., Bell K.P., Norenberg M.D. Glutamine synthetase: glial localization in brain. Science 1977 March 25, 195(4284):1356-1358.
26. Norenberg M.D., Martinez-Hernandez A. Fine structural localization of glutamine synthetase in astrocytes of rat brain. Brain Res 1979 February 2, 161(2):303-310.
27. Rao K.V., Panickar K.S., Jayakumar A.R., Norenberg M.D. Astrocytes protect neurons from ammonia toxicity. Neurochem Res 2005 October, 30(10):1311-1318.
28. Wright G., Davies N., Shawcross D., et al. Endotoxemia produces coma and brain swelling in bile duct ligated rats. Hepatology 2007, 45(6):1517-1526.
29. Lockwood A.H., McDonald J.M., Reiman R.E., et al. The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. JClin Invest 1979 March, 63(3):449-460.
30. Keiding S., Sorensen M., Bender D., Munk O.L., Ott P., Vilstrup H. Brain metabolism of 13N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology 2006 January, 43(1):42-50.
31. Keiding S., Sorensen M., Munk O.L., Bender D. Human (13)N-ammonia PET studies: the importance of measuring (13)N-ammonia metabolites in blood. Metab Brain Dis 2010 March, 25(1):49-56.
32. Sorensen M., Keiding S. New findings on cerebral ammonia uptake in HE using functional (13)N-ammonia PET. Metab Brain Dis 2007 December, 22(3-4):277-284.
33. Kato M., Hughes R., Keays R., Williams R. Electron microscopic study of brain capillaries in cerebral oedema from fulminant hepatic failure. Hepatology 1992, 15:1060-1066.
34. Traber P.G., Dal C.M., Ganger D.R., Blei A.T. Electron microscopic evaluation of brain edema in rabbits with galactosamine-induced fulminant hepatic failure: ultrastructure and integrity of the blood-brain barrier. Hepatology 1987 November, 7(6):1272-1277.
35. Kendall B.E., Kingsley D.P., Leonard J.V., Lingam S., Oberholzer V.G. Neurological features and computed tomography of the brain in children with ornithine carbamoyl transferase deficiency. JNeurol Neurosurg Psychiatr 1983 January, 46(1):28-34.
36. Norenberg M. Hepatic encephalopathy: studies with astrocyte cultures. The Biochemical Pathology of Astrocytes 1988, 451-464. Alan R. Liss, New York. M. Norenberg, L. Hertz, A. Schousboe (Eds.).
37. Rai V., Nath K., Saraswat V.A., Purwar A., Rathore R.K., Gupta R.K. Measurement of cytotoxic and interstitial components of cerebral edema in acute hepatic failure by diffusion tensor imaging. JMagn Reson Imaging 2008 August, 28(2):334-341.
38. Kale R.A., Gupta R.K., Saraswat V.A., et al. Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology 2006 April, 43(4):698-706.
39. Gove C.D., Hughes R.D., Ede R.J., Williams R. Regional cerebral edema and chloride space in galactosamine-induced liver failure in rats. Hepatology 1997 February, 25(2):295-301.
40. Nguyen J.H. Blood-brain barrier in acute liver failure. Neurochem Int 2012 June, 60(7):676-683.
41. Gibson G., Zimber A., Krook L., Richardson E.J., Visek W. Brain histology and behaviour of mice injected with urease. JNeuropathol 1974, 33:201-211.
42. Norenberg M. Alight and electron microscopic study of experimental portal-systemic (ammonia) encephalopathy. Lab Invest 1977, 36:618-627.
43. Gregorios J.B., Mozes L.W., Norenberg M.D. Morphologic effects of ammonia on primary astrocyte cultures. II. Electron microscopic studies. JNeuropathol Exp Neurol 1985 July, 44(4):404-414.
44. Alexander B., Li X., Benjamin I.S., Segal M.B., Sherwood R., Preston J.E. Aquantitative evaluation of the permeability of the blood brain barrier of portacaval shunted rats. Metab Brain Dis 2000 June, 15(2):93-103.
45. Chavarria L., Alonso J., Garcia-Martinez R., et al. Biexponential analysis of diffusion-tensor imaging of the brain in patients with cirrhosis before and after liver transplantation. AJNR Am J Neuroradiol 2011 September, 32(8):1510-1517.
46. Haussinger D., Kircheis G., Fischer R., Schleiss F., vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low grade oedema?. JHepatol 2000, 32:1035-1038.
47. Kimelberg H.K. Astrocytic swelling in cerebral ischemia as a possible cause of injury and target for therapy. Glia 2005 June, 50(4):389-397.
48. Shawcross D.L., Balata S., Olde Damink S.W., et al. Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemia. Am J Physiol Gastrointest Liver Physiol 2004 September, 287(3):G503-G509.
49. Cordoba J., Gottstein J., Blei A. Chronic hyponatremia exacerbates ammonia-induced brain oedema in rats after portacaval anastomosis. Hepatology 1998, 29(4):589-594.
50. Guevara M., Baccaro M.E., Torre A., et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 2009 June, 104(6):1382-1389.
51. Brusilow S.W., Koehler R.C., Traystman R.J., Cooper A.J. Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy. Neurotherapeutics 2010 October, 7(4):452-470.
52. Albrecht J., Norenberg M.D. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology 2006 October, 44(4):788-794.
53. Rao K.V., Norenberg M.D. Cerebral energy metabolism in hepatic encephalopathy and hyperammonemia. Metab Brain Dis 2001 June, 16(1-2):67-78.
54. Bernal W., Donaldson N., Wyncoll D., Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002 February 16, 359(9306):558-563.
55. Zwingmann C., Chatauret N., Leibfritz D., Butterworth R.F. Selective increase of brain lactate synthesis in experimental acute liver failure: results of a [H-C] nuclear magnetic resonance study. Hepatology 2003 February, 37(2):420-428.
56. Chatauret N., Zwingmann C., Rose C., Leibfritz D., Butterworth R.F. Effects of hypothermia on brain glucose metabolism in acute liver failure: a H/C-nuclear magnetic resonance study. Gastroenterology 2003 September, 125(3):815-824.
57. Rose C., Ytrebo L.M., Davies N.A., et al. Association of reduced extracellular brain ammonia, lactate, and intracranial pressure in pigs with acute liver failure. Hepatology 2007 December, 46(6):1883-1892.
58. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee.
59. Takada Y., Ishiguro S., Fukunaga K., et al. Increased intracranial pressure in a porcine model of fulminant hepatic failure using amatoxin and endotoxin. JHepatol 2001, 34:825-831.
60. Rolando N., Wade J., Davalos M., Wendon J., Philpott-Howard J., Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000, 32:734-739.
61. Vaquero J., Polson J., Chung C., et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 2003 September, 125(3):755-764.
62. Wright G., Shawcross D., Olde Damink S., Jalan R. Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. Metab Brain Dis 2007, 22(3-4):375-388.
63. Chastre A., Belanger M., Beauchesne E., Nguyen B.N., Desjardins P., Butterworth R.F. Inflammatory cascades driven by tumor necrosis factor-alpha play a major role in the progression of acute liver failure and its neurological complications. PLoS One 2012, 7(11):e49670.
64. Jalan R., Olde Damink S.W., Hayes P.C., Deutz N.E., Lee A. Pathogenesis of intracranial hypertension in acute liver failure: inflammation, ammonia and cerebral blood flow. JHepatol 2004 October, 41(4):613-620.
65. Aggarwal S., Kramer D., Yonas H., et al. Cerebral hemodynamic and metabolic changes in fulminant hepatic failure: a retrospective study. Hepatology 1994 January, 19(1):80-87.
66. Bemeur C., Qu H., Desjardins P., Butterworth R.F. IL-1 or TNF receptor gene deletion delays onset of encephalopathy and attenuates brain edema in experimental acute liver failure. Neurochem Int 2010 January, 56(2):213-215.
67. Jiang W., Desjardins P., Butterworth R. Cerebral inflammation contributes to encephalopathy and brain edema in acute liver failure: protective effect of minocycline. JNeurochem 2009, 109(2):485-493.
68. Jiang W., Desjardins P., Butterworth R. Minocycline attenuates oxidative/nitrosative stress and cerebral complications of acute liver failure in rats. Neurochem Int 2009 Dec, 55(7):601-605.
69. Shawcross D., Wright G., Olde Damink S., Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 2007, 22:125-138.
70. Shawcross D., Davies N., Williams R., Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. JHepatol 2004, 40(2):247-254.
71. Cauli O., Rodrigo R., Piedrafita B., Boix J., Felipo V. Inflammation and hepatic encephalopathy: ibuprofen restires learning ability in rats with portacaval shunts. Hepatology 2007, 46:514-519.
72. Rodrigo R., Cauli O., Gomez-Pinedo U., et al. Hyperammonemia induces neuroinflammation that contributes to cognitive impairment in rats with hepatic encephalopathy. Gastroenterology 2010 August, 139(2):675-684.
73. Zemtsova I., Gorg B., Keitel V., Bidmon H.J., Schror K., Haussinger D. Microglia activation in hepatic encephalopathy in rats and humans. Hepatology 2011 July, 54(1):204-215.
74. D'Mello C., Le T., Swain M.G. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. JNeurosci 2009 February 18, 29(7):2089-2102.
75. Gorg B., Bidmon H.J., Haussinger D. Gene expression profiling in the cerebral cortex of patients with cirrhosis with and without hepatic encephalopathy. Hepatology 2013 June, 57(6):2436-2447.
76. Gorg B., Bidmon H.J., Haussinger D. Gene expression profiling in the cerebral cortex of patients with cirrhosis with and without hepatic encephalopathy. Hepatology 2013 Jun, 57(6):2436-2447.
77. Marini J.C., Broussard S.R. Hyperammonemia increases sensitivity to LPS. Mol Genet Metab 2006 June, 88(2):131-137.
78. Felipo V., Urios A., Montesinos E., et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab Brain Dis 2012 March, 27(1):51-58.
79. Jover R., Rodrigo R., Felipo V., et al. Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: a model of hepatic encephalopathy in cirrhosis. Hepatology 2006 June, 43(6):1257-1266.
80. de Vries H.E., Blom-Roosemalen M.C., van Oosten M., et al. The influence of cytokines on the integrity of the blood-brain barrier invitro. JNeuroimmunol 1996 January, 64(1):37-43.
81. Didier N., Romero I.A., Creminon C., Wijkhuisen A., Grassi J., Mabondzo A. Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability. JNeurochem 2003 July, 86(1):246-254.
82. Chastre A., Belanger M., Nguyen B.N., Butterworth R.F. Lipopolysaccharide precipitates hepatic encephalopathy and increases blood-brain barrier permeability in mice with acute liver failure. Liver Int 2013 Jun 19, [Epub ahead of print]. 10.1111/liv.12252.
83. Bjerring P.N., Eefsen M., Hansen B.A., Larsen F.S. The brain in acute liver failure. A tortuous path from hyperammonemia to cerebral edema. Metab Brain Dis 2009 March, 24(1):5-14.
84. Bai G., Rama Rao K.V., Murthy C.R., Panickar K.S., Jayakumar A.R., Norenberg M.D. Ammonia induces the mitochondrial permeability transition in primary cultures of rat astrocytes. JNeurosci Res 2001 December 1, 66(5):981-991.
85. Zoratti M., Szabo I., De M.U. Mitochondrial permeability transitions: how many doors to the house?. Biochim Biophys Acta 2005 January 7, 1706(1-2):40-52.
86. Rama Rao K.V., Jayakumar A.R., Norenberg M.D. Role of oxidative stress in the ammonia-induced mitochondrial permeability transition in cultured astrocytes. Neurochem Int 2005 July, 47(1-2):31-38.
87. Vorobioff J., Bredfeldt J.E., Groszmann R.J. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983 January, 244(1):G52-G57.
88. Cirera I., Bauer T.M., Navasa M., et al. Bacterial translocation of enteric organisms in patients with cirrhosis. JHepatol 2001 January, 34(1):32-37.
89. Llovet J.M., Bartoli R., March F., et al. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. JHepatol 1998 February, 28(2):307-313.
90. Perez del P.S., Pizcueta P., Engel P., Bosch J. Enhanced monocyte activation and hepatotoxicity in response to endotoxin in portal hypertension. JHepatol 2000 January, 32(1):25-31.
91. Bigatello L.M., Broitman S.A., Fattori L., et al. Endotoxemia, encephalopathy, and mortality in cirrhotic patients. Am J Gastroenterol 1987 January, 82(1):11-15.
92. Rajkovic I.A., Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986 March, 6(2):252-262.
93. Rajkovic I.A., Williams R. Mechanisms of abnormalities in host defences against bacterial infection in liver disease. Clin Sci (Lond) 1985 March, 68(3):247-253.
94. Shawcross D.L., Shabbir S.S., Taylor N.J., Hughes R.D. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2010 March, 51(3):1062-1069.
95. Shawcross D., Wright G., Stadlbauer V., et al. Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology 2008 October, 48(4):1202-1212.
96. Taylor N.J., Nishtala A., Manakkat Vijay G.K., et al. Circulating neutrophil dysfunction in acute liver failure. Hepatology 2013 March, 57(3):1142-1152.
97. Manakkat Vijay G.K., Abeles R.D., Ramage S., et al. Neutrophil intracellular toll-like receptor (TLR9) expression serves as a biomarker that determines presence and severity of encephalopathy in acute liver failure and cirrhosis. JHepatol 2012, 56(suppl 2):S102-S103. Ref Type: Abstract.
98. Harrison P.M., Keays R., Bray G.P., Alexander G.J., Williams R. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990 June 30, 335(8705):1572-1573.
99. Ytrebo L.M., Korvald C., Nedredal G.I., Elvenes O.P., Nielsen Grymyr O.J., Revhaug A. N-acetylcysteine increases cerebral perfusion pressure in pigs with fulminant hepatic failure. Crit Care Med 2001 October, 29(10):1989-1995.
100. Harrison P., Wendon J., Williams R. Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure. Hepatology 1996 May, 23(5):1067-1072.
101. Dhanda S., Kaur S., Sandhir R. Preventive effect of N-acetyl-l-cysteine on oxidative stress and cognitive impairment in hepatic encephalopathy following bile duct ligation. Free Radic Biol Med 2013 Mar, 56:204-215.
102. Tofteng F., Larsen F.S. The effect of indomethacin on intracranial pressure, cerebral perfusion and extracellular lactate and glutamate concentrations in patients with fulminant hepatic failure. JCereb Blood Flow Metab 2004 July, 24(7):798-804.
103. Chung C., Gottstein J., Blei A.T. Indomethacin prevents the development of experimental ammonia-induced brain edema in rats after portacaval anastomosis. Hepatology 2001 August, 34(2):249-254.
104. Henry C.J., Huang Y., Wynne A., et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. JNeuroinflammation 2008, 5:15.
105. Larsen F.S., Hansen B.A., Ejlersen E., et al. Cerebral blood flow, oxygen metabolism and transcranial Doppler sonography during high-volume plasmapheresis in fulminant hepatic failure. Eur J Gastroenterol Hepatol 1996 March, 8(3):261-265.
106. Jalan R., Olde Damink S., Deutz N., Lee A., Hayes P. Treatment of uncontrolled intracranial hypertension in acute liver failure with moderate hypothermia. Lancet 1999, 354:1164-1168.
107. Jalan R., Olde Damink S., Deutz N., Hayes P., Lee A. Restoration of cerebral blood flow autoregulation and reactivity to carbon dioxide in acute liver failure by moderate hypothermia. Hepatology 2001 July, 34:50-54.
108. Jalan R., Olde Damink S., Deutz N., et al. Moderate hypothermia prevents cerebral hyperemia and increase in intracranial pressure in patients undergoing liver transplantation for acute liver failure. Transplantation 2003, 75(12):2034-2039.
109. Shawcross D.L., Wendon J.A. The neurological manifestations of acute liver failure. Neurochem Int 2011 November 2.
110. Jalan R., Schnurr K., Mookerjee R., et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009, 50(2):555-564.
111. Garcia-Martinez R., Caraceni P., Bernardi M., Gines P., Arroyo V., Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 2013 Nov, 58(5):1836-1846.
112. Jalan R., Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci 2004, 106(5):467-474.
113. Stadlbauer V., Mookerjee R., Wright G., et al. Role of toll-like receptors 2, 4 and 9 in mediating neutrophils dysfunction in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol 2009, 296(1):G15-G22.
114. Simon-Talero M., Garcia-Martinez R., Torrens M., et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. JHepatol 2013 December, 59(6):1184-1192.
115. Hassanein T.I., Tofteng F., Brown R.S., et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007 December, 46(6):1853-1862.
116. Sen S., Williams R., Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002 April, 22(suppl 2):5-13.
117. Thiel K., Proven A., Davies N., et al. The development and testing of the University College London Liver Support Device (ARSENEL): improvement in survival in paracetamol-induced acute liver failure pigs. Gut 2012, 59(2). Ref Type: Abstract.
118. Antoniades C.G., Berry P.A., Wendon J.A., Vergani D. The importance of immune dysfunction in determining outcome in acute liver failure. JHepatol 2008 November, 49(5):845-861.
119. Antoniades C., Berry P., Wendon J., Vergani D. The importance of immune dysfunction in determining outcome in acute liver failure. JHepatol 2008, 49:845-861.
120. Bass N.M., Mullen K.D., Sanyal A., et al. Rifaximin treatment in hepatic encephalopathy. NEngl J Med 2010 March 25, 362(12):1071-1081.
121. Bajaj J.S., Heuman D.M., Wade J.B., et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011 February, 140(2):478-487.
122. Kalambokis G.N., Tsianos E.V. Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology 2012 February, 55(2):655-656.
123. Liu Q., Duan Z.P., Ha dK., Bengmark S., Kurtovic J., Riordan S.M. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004 May, 39(5):1441-1449.
124. Stadlbauer V., Mookerjee R., Hodges S., Wright G., Davies N., Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. JHepatol 2008, 48(6):945-951.
125. Bajaj J.S., Saeian K., Christensen K.M., et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008 July, 103(7):1707-1715.
126. Pereg D., Kotliroff A., Gadoth N., Hadary R., Lishner M., Kitay-Cohen Y. Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition 2011 February, 27(2):177-181.